Literature DB >> 25488714

Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta).

K R Kelly1,2, B H Pypendop3, K L Christe1,4.   

Abstract

Recently, tramadol and its active metabolite, O-desmethyltramadol (M1), have been studied as analgesic agents in various traditional veterinary species (e.g., dogs, cats, etc.). This study explores the pharmacokinetics of tramadol and M1 after intravenous (IV) and oral (PO) administration in rhesus macaques (Macaca mulatta), a nontraditional veterinary species. Rhesus macaques are Old World monkeys that are commonly used in biomedical research. Effects of tramadol administration to monkeys are unknown, and research veterinarians may avoid inclusion of this drug into pain management programs due to this limited knowledge. Four healthy, socially housed, adult male rhesus macaques (Macaca mulatta) were used in this study. Blood samples were collected prior to, and up to 10 h post-tramadol administration. Serum tramadol and M1 were analyzed using liquid chromatography-mass spectrometry. Noncompartmental pharmacokinetic analysis was performed. Tramadol clearance was 24.5 (23.4-32.7) mL/min/kg. Terminal half-life of tramadol was 111 (106-127) min IV and 133 (84.9-198) min PO. Bioavailability of tramadol was poor [3.47% (2.14-5.96%)]. Maximum serum concentration of M1 was 2.28 (1.88-2.73) ng/mL IV and 11.2 (9.37-14.9) ng/mL PO. Sedation and pruritus were observed after IV administration.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25488714      PMCID: PMC4461566          DOI: 10.1111/jvp.12194

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  35 in total

1.  Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol.

Authors:  Emilio García Quetglas; Jose Ramón Azanza; Ernesto Cardenas; Belén Sádaba; Miguel Angel Campanero
Journal:  Biopharm Drug Dispos       Date:  2007-01       Impact factor: 1.627

2.  Effect of the opioid analgesic tramadol on inactivation of norepinephrine and serotonin.

Authors:  H H Hennies; E Friderichs; K Wilsmann; L Floh e
Journal:  Biochem Pharmacol       Date:  1982-04-15       Impact factor: 5.858

Review 3.  Clinical pharmacology of tramadol.

Authors:  Stefan Grond; Armin Sablotzki
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations.

Authors:  K A Lehmann; U Kratzenberg; B Schroeder-Bark; G Horrichs-Haermeyer
Journal:  Clin J Pain       Date:  1990-09       Impact factor: 3.442

5.  Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids.

Authors:  H H Hennies; E Friderichs; J Schneider
Journal:  Arzneimittelforschung       Date:  1988-07

6.  Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.

Authors:  Julia Kirchheiner; Jan-Tobias H A Keulen; Steffen Bauer; Ivar Roots; Jürgen Brockmöller
Journal:  J Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.153

7.  Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats.

Authors:  B H Pypendop; J E Ilkiw
Journal:  J Vet Pharmacol Ther       Date:  2008-02       Impact factor: 1.786

8.  Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction.

Authors:  R E Johnson; E J Cone; J E Henningfield; P J Fudala
Journal:  Clin Pharmacol Ther       Date:  1989-09       Impact factor: 6.875

9.  Bioavailability of enteral tramadol formulations. 1st communication: capsules.

Authors:  W Lintz; H Barth; G Osterloh; E Schmidt-Böthelt
Journal:  Arzneimittelforschung       Date:  1986-08

10.  Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites.

Authors:  W N Wu; L A McKown; S Liao
Journal:  Xenobiotica       Date:  2002-05       Impact factor: 1.908

View more
  3 in total

1.  Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin-induced neuropathic cold hypersensitivity.

Authors:  Yuka Shidahara; Shinya Ogawa; Mari Nakamura; Shingo Nemoto; Yuji Awaga; Miyuki Takashima; Aldric Hama; Akihisa Matsuda; Hiroyuki Takamatsu
Journal:  Pharmacol Res Perspect       Date:  2016-02-08

2.  Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography.

Authors:  Ryosuke Arakawa; Akihiro Takano; Christer Halldin
Journal:  Int J Neuropsychopharmacol       Date:  2019-01-01       Impact factor: 5.176

3.  Toxicokinetics of U-47700, tramadol, and their main metabolites in pigs following intravenous administration: is a multiple species allometric scaling approach useful for the extrapolation of toxicokinetic parameters to humans?

Authors:  Frederike Nordmeier; Iryna Sihinevich; Adrian A Doerr; Nadja Walle; Matthias W Laschke; Thorsten Lehr; Michael D Menger; Peter H Schmidt; Markus R Meyer; Nadine Schaefer
Journal:  Arch Toxicol       Date:  2021-10-03       Impact factor: 5.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.